<DOC>
	<DOCNO>NCT00002480</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Radiation therapy may effective treatment prostate cancer . PURPOSE : Phase I trial study effectiveness radiation therapy treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose radiotherapy use 3-dimensional ( 3D ) conformal technique patient stage II III adenocarcinoma prostate . II . Determine morbidity high-dose 3D conformal therapy patient . OUTLINE : This dose escalation study . Patients undergo 3-dimensional conformal radiotherapy 4-5 day week least 8 week . Cohorts 20-40 patient receive escalate dos radiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose 10 % patient experience dose-limiting toxicity . Patients follow 3 month , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A minimum 40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Locally advance ( T2cT3 ) adenocarcinoma prostate include : Bulky tumor confine prostate ( stage II ) Tumors extend beyond capsule ( stage III ) PSA great 20 ng/mL No regional lymph node involvement ( CT scan surgical sampling ) No distant metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 11 g/dL Hepatic : Not specify Renal : Not specify Other : No major medical psychiatric illness would preclude study No metallic pelvic prosthesis PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Prior hormonal therapy allow Radiotherapy : No prior radiotherapy ( include pelvic irradiation ) Surgery : No prior radical surgery carcinoma prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>